<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01822041</url>
  </required_header>
  <id_info>
    <org_study_id>ARN-509-006</org_study_id>
    <secondary_id>2012-004899-19</secondary_id>
    <nct_id>NCT01822041</nct_id>
  </id_info>
  <brief_title>14C-ARN-509 Microtracer Label AME and Absolute BA Study</brief_title>
  <official_title>14C-ARN-509 Microdose Absolute Bioavailability and Microtracer Absorption, Metabolism, and Excretion Study in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aragon Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aragon Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is study in healthy human volunteers to determine the absorption, metabolism, and
      excretion (AME) profile of ARN-509 as well as its absolute oral bioavailability (BA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two cohorts of 6 healthy volunteers will be enrolled for the AME and absolute BA parts,
      respectively. The dose for both cohorts is 240 mg. The expected exposure of the dose is
      7-fold lower than the steady state reached in patients with castration-resistant prostate
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance</measure>
    <time_frame>2 months 10 days</time_frame>
    <description>To determine the rate and routes of excretion of ARN-509 in urine, feces, and expired air</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Oral Bioavailability</measure>
    <time_frame>2 months 10 days</time_frame>
    <description>To determine absolute oral bioavailability of ARN-509</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite Profile</measure>
    <time_frame>2 months 10 days</time_frame>
    <description>To identify and quantify the ARN-509 metabolites in plasma, urine, and feces</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A - 14C labeled ARN-509</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 Î¼g (9.25 kBq, 250 nCi) 14C-ARN-509</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: 14C labeled ARN-509</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARN-509</intervention_name>
    <description>Single oral dose of 240 mg ARN-509</description>
    <arm_group_label>Part A - 14C labeled ARN-509</arm_group_label>
    <arm_group_label>Part B: 14C labeled ARN-509</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Gender : male

          2. Age : 50 - 80 years, inclusive

          3. Body Mass Index (BMI) : 18.5-30.0 kg/m2

          4. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages
             or food (coffee, tea, cola, chocolate, &quot;power drinks&quot;), grapefruit (juice) and tobacco
             products from 48 h prior to entry in the clinical research center until discharge

          5. Medical history without major pathology

        Key Exclusion Criteria:

          1. Evidence of clinically relevant pathology.

          2. Mental handicap.

          3. History of relevant drug and/or food allergies.

          4. Regular/routine treatment with non-topical medications within 30 days prior to entry
             into the clinical research center.

          5. Smoking.

          6. History of alcohol abuse or drug addiction (including soft drugs like cannabis
             products).

          7. Use of concomitant medication, except for acetaminophen (paracetamol) and topical
             medications

          8. Irregular defecation pattern (less than once per 2 days).

          9. Positive drug screen (opiates, methadone, cocaine, amphetamines, cannabinoids,
             barbiturates, benzodiazepines, and alcohol).

         10. Intake of more than 24 units of alcohol per week (one unit of alcohol equals
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits).

         11. Positive screen on HBsAg, anti-HCV or anti-HIV 1/2.

         12. Illness within five days prior to drug administration.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nada al Kotbi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA International Group BV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Pruim-Tait, MA, MSc</last_name>
    <role>Study Director</role>
    <affiliation>PRA International Group BV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA - Clinical Research Unit, University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2013</study_first_submitted>
  <study_first_submitted_qc>March 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2013</study_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>mass balance study</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

